BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

It also means that most regulatory watchers may not be looking at the appropriate endpoint for calculating and comparing relative cycle times. In most cases, the EC agrees with the CHMP's ...

NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

PTC Therapeutics Inc (PTCT) reports strong Q3 revenue and raises 2024 guidance, while navigating regulatory hurdles and ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

An SAG meeting was also convened to address questions raised by the CHMP when it evaluated Biogen ... as the lead of lecanemab development and regulatory submissions globally, with both Eisai ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.

Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company’s President ...

On the regulatory front, CSL secures partner in Japan ... The process is near completion with the CHMP opinion expected next month. As we look forward to achieving marketing approval in the US, we ...

Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET. Company Participants. Stéphane Paquette - VP, Corporate Development Krish Krishn ...